Severe eczema is a Type 2 inflammatory disease.
Moderate to severe atopic dermatitis is more than a skin condition — it is systemic IL-4/IL-13-driven inflammation with barrier dysfunction. Modern care offers far more than topical steroids.
Daily impact
Persistent itch fragments sleep, undermines focus and confidence, and erodes mental health. Visible flares affect intimacy, work and social life — a chronic burden that often goes underrecognized in standard care.
When to seek specialized care
- Persistent itch interrupting sleep
- Wide body surface involvement or recurrent flares
- Reliance on oral or systemic steroids
- Inadequate response to potent topical therapy
- Coexisting asthma, food allergy, rhinitis or eosinophilia
- Significant emotional or social impact
How we evaluate
We assess severity (extent, itch, sleep, quality-of-life impact), characterize barrier dysfunction and trigger patterns, screen for systemic type 2 comorbidities, and review prior therapy ladder to orient on advanced options.
Advanced treatment options
Beyond emollients and topical steroids, modern care includes biologics targeting IL-4/IL-13 (dupilumab), IL-13 (tralokinumab, lebrikizumab), IL-31Rα (nemolizumab) and oral JAK inhibitors. We orient on candidacy within current evidence and approved indications.
Eczema is part of the atopic march.
Atopic dermatitis frequently coexists with airway, allergic and eosinophilic disease driven by shared IL-4/IL-13 biology. A unified type 2 evaluation across organ systems often reframes the long-term plan.